Lung Cancer Management

• Outstanding faculty of noted oncology experts - co-chaired by

Roy S. Herbst, MD, PhD Professor of Medicine   and Cancer Biology Department of Thoracic/Head   and Neck Medical Oncology The University of Texas   M.D. Anderson Cancer Center Houston, Texas

Corey J. Langer, MD, FACP Professor of Medicine Hematology-Oncology Division Department of Medicine University of Pennsylvania Philadelphia, Pennsylvania

• Timely and engaging information
  
• Continuous program updates, news, and announcements
  
• E-mail notification when each course becomes available
  
• Lung cancer CME program offers CME credit, CE credit or CPE credit
  
• Certificate of advanced study in lung cancer management awarded upon completion/submission of the posttests and evaluations for all courses in each curriculum.
  

Intensive ongoing curriculum explores both non–small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC)

• NCCN Lung Cancer Treatment Guidelines
• Lung Cancer Risk Factors and Risk Assessment
• Screening and Early Detection of Lung Cancer
• Diagnostic Advances and Lung Cancer Symptoms
• Advances in Lung Cancer Staging Systems
  • Using TNM classification of malignant tumors in NSCLC (stages IA, IB, IIA, IIB, IIIA, IIIB, IV [metastatic]; early, locally advanced, and advanced tumors)
  • Using limited stage and extensive stages in SCLC
• Management of Bronchioloalveolar Carcinoma (BAC)
• Current and Emerging Innovative Lung Cancer Treatment Options and Strategies
  • Surgery update
  • Chemotherapy—including newer agents, such as paclitaxel, pralatrexate, and talotrexin
  • Chemoradiation
  • Neoadjuvant and adjuvant chemotherapy
  • Consolidative chemotherapy
  • Practice-changing data on targeted therapies: vascular endothelial growth factor (VEGF) inhibitors, epidermal growth factor (EGF) inhibitors, matrix metalloprotease (MMP) inhibitors, farnesyltransferase (FT) inhibitors, multikinase inhibitors, inhibitors of Ras, HDAC, mTOR, Met, MEK, toll, and p13K, which include the following drugs, among others: gefitinib, erlotinib, bevacizumab, sunitinib, sorafenib, lonafarnib, vandetanib, cetuximab
• Personalized Treatment of Lung Cancer
• PCI in Lung Cancer
• Maintenance Therapy
• Management of Special Populations (eg, women, nonsmokers)
• Supportive Care
  

• Assess molecular pathways, targets, histotypes, mutation status, and new staging systems for lung cancer, to improve diagnosis and associated treatment decisions that improve patient outcomes.


• Apply knowledge of MOA, efficacy, and safety of current and emerging agents indicated for the treatment of patients with lung cancer, with consideration of meaningful endpoints, in order to optimize clinical outcomes.


• Integrate personalized medicine methodologies to customize therapies for patients with lung cancer, based on an understanding of molecular and genetic factors associated with the disease, gender differences, never-smokers vs smoker differences, and considerations in the elderly.